Medpace Reports Q3 Earnings Beat and Authorizes $1 Billion Buyback

On October 21, Medpace reported third-quarter 2026 revenue of $716.0 million, up 8.5% year over year, with net income of $137.5 million and diluted EPS of $4.84. EBITDA increased 16.0% to $172.1 million, while net new business awards rose 10.6% year over year to $873.4 million. The board replaced its existing repurchase authorization with a new program allowing up to $1 billion in buybacks, and Medpace raised or reaffirmed its 2026 outlook at $2.835 billion to $2.855 billion of revenue and $17.97 to $18.32 of diluted EPS.

The results provide investors with stronger quarterly profitability and bookings momentum, while the $1 billion authorization creates additional potential demand for Medpace shares. The 2026 revenue and EPS ranges set the company’s near-term financial framework, and the authorization replaces the prior program effective October 20, 2026.

  • 1Third-quarter 2026 revenue increased 8.5% year over year to $716.0 million, and GAAP net income was $137.5 million, or $4.84 per diluted share.
  • 2Third-quarter EBITDA rose 16.0% year over year to $172.1 million, producing an EBITDA margin of 24.0%.
  • 3Net new business awards increased 10.6% year over year to $873.4 million in the third quarter of 2026.
  • 4The board approved repurchases of up to $1 billion effective October 20, 2026, after terminating the existing authorization.
  • 5Medpace expects 2026 revenue of $2.835 billion to $2.855 billion, EBITDA of $638 million to $652 million, net income of $514 million to $524 million, and diluted EPS of $17.97 to $18.32.
  • Material 6 describes 2026 EPS guidance as $18.15, while materials 10, 14 and 15 report a range of $17.97 to $18.32; the relationship between the single figure and the reported range is not specified.

Sources